VIR-5500 targets PSMA and is being tested in a phase 1 trial for mCRPC, including combination therapy with ARPIs. Interim data showed PSA reductions in all patients and a favorable safety profile, ...
Men who are further along in their fertility journey were found to be less likely to be using testosterone, according to recent data presented at the 26h Annual Fall Scientific Meeting of the Sexual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback